Find Psychiatry/Psychology Drugs in Phase II Clinical Development in UNITED STATES

Lead Product(s): BTRX-140

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

The Phase 2 proof-of-concept trial is designed to evaluate the efficacy, safety and tolerability of BTRX-140 in approximately 120 patients with major depressive disorder.

Lead Product(s): Ketamine Hydrochloride,Venlafaxine,Sertraline Hydrochloride

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

It showed 60 milligrams of SLS-002 to be safe and well tolerated as a monotherapy or with an oral antidepressant.

Lead Product(s): NW-3509

Therapeutic Area: Psychiatry/Psychology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

FDA approved the plan proposed by Newron as well as the protocol for a first, four-week explanatory study in patients with schizophrenia, expected to start enrolling patients in the next few days.